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a  b  s  t  r  a  c  t
ackground  and  objectives:  India  has  the highest  under-ﬁve  death  toll  globally,  approximately  20%  of which  is attributed  to vaccine-preventable  diseases.
ndia’s  Universal  Immunization  Programme  (UIP)  is working  both  to  increase  immunization  coverage  and  to introduce  new  vaccines.  Here,  we  analyze
he  disease  and  ﬁnancial  burden  alleviated  across  India’s  population  (by  wealth  quintile,  rural  or urban  area,  and  state)  through  increasing  vaccination
ates  and  introducing  a rotavirus  vaccine.
ethods:  We  use  IndiaSim,  a simulated  agent-based  model  (ABM)  of the  Indian  population  (including  socio-economic  characteristics  and  immunization
tatus)  and  the health  system  to model  three  interventions.  In the  ﬁrst  intervention,  a rotavirus  vaccine  is introduced  at the  current  DPT3  immunization
overage  level  in  India.  In the  second  intervention,  coverage  of  three  doses  of  rotavirus  and  DPT  and  one  dose  of the measles  vaccine  are  increased  to
0%  randomly  across  the  population.  In the third,  we  evaluate  an  increase  in immunization  coverage  to 90%  through  targeted  increases  in  rural  and
rban  regions  (across  all  states)  that  are  below  that level  at baseline.  For  each  intervention,  we evaluate  the  disease  and  ﬁnancial  burden  alleviated,  costs
ncurred,  and  the cost  per  disability-adjusted  life-year  (DALY)  averted.
esults: Baseline  immunization  coverage  is low  and  has  a large  variance  across  population  segments  and  regions.  Targeting  speciﬁc  regions  can  approx-
mately  equate  the rural  and  urban  immunization  rates.  Introducing  a rotavirus  vaccine  at the  current  DPT3  level  (intervention  one)  averts  34.7 (95%
ncertainty  range  [UR],  31.7–37.7)  deaths  and  $215,569  (95%  UR,  $207,846–$223,292)  out-of-pocket  (OOP)  expenditure  per  100,000  under-ﬁve  children.
ncreasing  all  immunization  rates  to  90%  (intervention  two)  averts  an  additional  22.1  (95%  UR,  18.6–25.7)  deaths  and  $45,914  (95% UR,  $37,909–$53,920)
OP  expenditure.  Scaling  up  immunization  by  targeting  regions  with  low  coverage  (intervention  three)  averts  a  slightly  higher  number  of deaths  and  OOP
xpenditure.  The  reduced  burden  of  rotavirus  diarrhea  is  the  primary  driver  of  the  estimated  health  and  economic  beneﬁts  in  all  intervention  scenarios.
ll three  interventions  are  cost  saving.
onclusion:  Improving  immunization  coverage  and  the introduction  of  a rotavirus  vaccine  signiﬁcantly  alleviates  disease  and  ﬁnancial  burden  in  Indian
ouseholds.  Population  subgroups  or  regions  with  low  existing  immunization  coverage  beneﬁt  the  most  from  the  intervention.  Increasing  coverage  by
argeting  those  subgroups  alleviates  the  burden  more  than  simply  increasing  coverage  in the  population  at  large.
©  2014 Published  by  Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
India has the largest number of under-ﬁve deaths in the world
1]. Vaccine-preventable diseases are a major contributor to the
urden, causing approximately 20% of under-ﬁve deaths in South-
ast Asia [2]. In 1985 India launched its Universal Immunization
rogramme (UIP), which provides free vaccines for measles,
oliomyelitis, tuberculosis (BCG), hepatitis B, and diphtheria,
∗ Corresponding author at: Center for Disease Dynamics, Economics & Policy,
ashington, DC, USA.
E-mail address: ramanan@cddep.org (R. Laxminarayan).
ttp://dx.doi.org/10.1016/j.vaccine.2014.04.080
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bpertussis, tetanus (DPT). Despite these efforts, each year more than
50,000 children under the age of ﬁve die from measles in India (44%
of global under-ﬁve measles deaths) [3]. India accounts for 56%
(2525) of global diphtheria cases, 18% (44,154) of pertussis cases,
and 23% (2404) of tetanus cases [4]. The UIP has yet to incorporate
existing vaccines against mumps, pneumococcal disease and
rotavirus.
In the Global Immunization Vision and Strategy (GIVS) from
2005, the World Health Organization (WHO) and the United
Nations Children’s Fund (UNICEF) set a goal for all countries to
achieve 90% national vaccination coverage and 80% coverage in
every district by 2010 [5]. The UIP has fallen short of these targets. In
2007 only 53.5% of children were fully vaccinated, and vaccination
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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overage varied considerably across the country [6]. Immunization
overage is predicted to have improved in recent years, but full
overage remains below 70% in urban areas and below 60% in rural
reas [7].
Rotavirus vaccines were ﬁrst introduced in national immu-
ization programs in 2006 as a key intervention to address
he burden of diarrheal disease. By January 2014, 53 coun-
ries had introduced rotavirus vaccines [8]. These vaccines have
he potential to signiﬁcantly alleviate the disease and ﬁnan-
ial burden in India, where each year approximately 113,000
nder-ﬁves die from rotavirus (39% of diarrhea cases). Indi-
ns spend between $37.4 million and $66.8 million annually
n direct medical costs of rotavirus diarrhea hospitalizations
n children under ﬁve (457,000–884,000) and outpatient treat-
ent (2 million visits) [9]. In 2014 Indian regulators licensed the
ndian-made vaccine 116E following a successful Phase 3 trial
10,11].
In this paper we evaluate the health and ﬁnancial effects
f interventions introducing a rotavirus vaccine to the immu-
ization program and increasing the immunization coverage of
he DPT3 and measles vaccines. We  build on IndiaSim [12], a
imulated agent-based model (ABM) of the Indian population
nd health system, and use household-level data on immu-
ization decisions. We  simulate three intervention scenarios: (i)
he introduction of the rotavirus vaccine at the current DPT3
evel; (ii) an increase in DPT3, measles, and rotavirus vac-
ination coverage to 90% (the GIVS target) randomly across
ndian households; and (iii), targeted state-level and rural–urban
mplementation that increases coverage in sub-regions that
re below 90% immunization coverage in the baseline sce-
ario.
Our analysis does not include the beneﬁts of poliomyelitis
mmunization. India is polio-free and any changes in the coverage
evel of the poliomyelitis vaccine will not yield additional health or
conomic beneﬁts. We also omit the BCG vaccine from the analysis:
he burden of miliary tuberculosis is low [13], and BCG coverage is
igh in India [14].
. Methods
.1. Population sample
IndiaSim is populated with data from the District Level House-
old Survey (DLHS-3, conducted during 2007–08) of India [6].
LHS data are representative at the district level and cover
ore than 720,000 households and 3.8 million individuals from
01 districts. The survey data include indicators on demo-
raphics, household socioeconomic status, household vaccination
hoices of UIP vaccines, and other indicators of health-seeking
ehavior. The simulations are based on a randomly selected sub-
et of 128,000 households comprising approximately 750,000
ndividuals.
.2. Disease, vaccination, and treatment data
Table 1 presents the input data on the epidemiology, treatment,
nd prevention of DPT, measles, and rotavirus. DPT and measles
ncidences are calibrated using the case-fatality rates (CFR) and
he GBD 2010 mortality rates [15]. Rotavirus incidence [16] is dis-
ributed across wealth quintiles according to Rheingans et al. [17],
nd CFR is calibrated to that incidence and the mortality rate [18].
e do not include comorbidity of diseases because of a paucity of
ata.S (2014) A151–A161
In the absence of data to parameterize a demand function for
treatment of vaccine-preventable diseases, we  assume that every-
one who  contracts a vaccine-preventable disease seeks treatment.
We do not model the effect of treatment on disease transmission.
We assume that the baseline level of treatment utilization results
in the realized baseline incidence and mortality rates in the pop-
ulation. In addition, we  assume that the demand and supply of
treatment for individuals with disease is equivalent across all simu-
lation scenarios. Treatment costs for DPT and measles are estimated
from the National Sample Survey (NSS) 60th round schedule 25
[19], and treatment costs for rotavirus are from Tate et al. [9]. All
costs in the model are in 2013 US dollars.
Total routine immunization cost is the sum of costs for vac-
cines, personnel, vehicles and transportation, cold chain equipment
and maintenance, and program and other recurrent costs, includ-
ing planning, supervision, monitoring, and surveillance. The data
were collected from the Ministry of Health and Family Welfare
(MoHFW) by personal communication. We  use the WHO  com-
prehensive multi-year planning (cMYP) for immunization tool to
analyze the data and assume that interventions are introduced in
2016. Costs include program as well as vaccine costs and are not
separable by vaccine type.
Baseline vaccination coverage rates are from 2011 estimates
[14].
2.3. Income data
The gross domestic product (GDP) per capita for India is from the
World Bank [20]. The distribution across wealth quintiles is from
NSS expenditure data. The state-level GDP per capita is from the
Indian government’s Press Information Bureau [21].
2.4. Model
IndiaSim is an iterative, stochastic ABM. The model comprises 67
regions, representing the urban and rural areas of 34 Indian states
and districts. Nagaland is not included in the model because it is
omitted from DLHS-3, and the urban area of Andaman and Nicobar
is dropped because of a low number of observations. Each region
comprises a set of representative households. A set of character-
istics describes each household (socioeconomic indicators) and its
individuals (age and sex). An iteration of a simulation represents a
day (the timestep of the model).
Individuals in the model are in one of several disease states:
they are healthy or they suffer from diphtheria, pertussis, tetanus,
measles, and/or rotavirus. They contract diseases based on a
stochastic function of their characteristics (age, sex, and wealth
quintile) and their immunization history. Those suffering from dis-
ease seek treatment at public or private facilities based on the
average treatment-seeking rates by income quintile in the DLHS-
3 data. Births in the model are based on a household-level probit
regression model that is bounded to the state-level fertility rates
[12]. Deaths not related to the ﬁve diseases in the model are deter-
mined on the basis of WHO  life tables [22].
We assume that households that immunized previously born
children in the baseline DLHS-3 data will immunize any children
born during the simulation with those vaccines. To increase the
urban and rural sub-region rates to 2011 estimates, we  select a
random set of households to also vaccinate. In the intervention sce-
narios, to scale up the coverage rates, the model makes additional
households vaccination compliant. The method of selecting these
extra households varies across scenarios (e.g., random or targeted
by state and region).
The model was programmed in C++.
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Table  1
Disease and intervention parameters.
Variable Base-case estimate Sensitivity range Source
Diphtheria
Incidence (per 100,000) Based on [15] and CFR
<1  year 42.2 29.5–54.8
1–5  years 18.3 12.8–23.8
CFR 0.012 0.008–0.016 [37]
Cost of seeking treatment
Public facilities $0.35 $0.25–$0.46 [19]
Private facilities $0.37 $0.26–$0.49
Treatment cost
Public facilities $3.51 $2.45–$4.56 [19]
Private facilities $4.59 $3.21–$5.97
DPT3 vaccination relative risk reduction 0.955 0.921–0.989 [38]
Pertussis
Incidence (per 100,000) Based on [15] and CFR
<1  year 2123.2 1486.3–2760.2
1–5  years 313.4 219.4–407.5
CFR [39]
<1 year 0.037 0.026–0.048
1–4.9 years 0.010 0.007–0.013
Cost of seeking treatment [19]
Public facilities $0.72 $0.50–$0.93
Private facilities $0.77 $0.54–$1.00
Treatment cost [19]
Public facilities $5.83 $4.08–$7.58
Private facilities $7.63 $5.34–$9.92
DPT3 vaccination relative risk reduction 0.840 0.680–1.00 [40]
Tetanus
Incidence (per 100,000) Based on [15] and CFR
<1  year 637.1 446.0–828.2
1–5  years 3.2 2.2–4.1
CFR [41]
<1 months 0.864 0.648–1.000
1  month–5 years 0.328 0.230–0.427
Cost of seeking treatment [19]
Public facilities $0.55 $0.38–$0.71
Private facilities $0.58 $0.41–$0.76
Treatment cost [19]
Public facilities $3.54 $2.48–$4.60
Private facilities $4.63 $3.24–$6.02
DPT3 vaccination relative risk reduction 1.000 .990–1.00 [42]
DPT3 vaccination baseline coverage 76.8% Based on [6,14]
Measles
Incidence (per 100,000) Based on [15] and CFR
<1  year 4776.9 3343.9–6210.0
1–5  years 2723.3 1906.3–3540.3
CFR 0.015 0.011–0.020 [45]
Cost of seeking treatment
Public facilities $1.24 $0.87–$1.61 [19]
Private facilities $1.32 $0.92–$1.72
Treatment cost $5.92 $4.14–$7.69
Vaccination relative risk reduction 0.840 0.83–0.87 [43]
Vaccination baseline coverage 82.2% Based on [6,14]
Rotavirus
Incidence (per child-year) Based on [9,16,17]
<6 months quintile I 1.38 0.96–1.79
Quintile II 1.17 0.89–1.52
Quintile III 0.97 0.68–1.25
Quintile IV 0.76 0.53–0.98
Quintile V 0.50 0.35–0.65
6  months–1 year quintile I 2.08 1.46–2.70
Quintile II 1.81 1.27–2.35
Quintile III 1.53 1.07–1.99
Quintile IV 1.15 0.80–1.49
Quintile V 0.76 0.53–0.98
1–2  years quintile I 1.74 1.22–2.26
Quintile II 1.44 1.00–1.87
Quintile III 1.24 0.87–1.61
Quintile IV 0.94 0.66–1.22
Quintile V 0.59 0.42–0.77
2–5  years quintile I 1.11 0.78–1.44
Quintile II 0.94 0.66–1.23
Quintile III 0.78 0.55–1.01
Quintile IV 0.59 0.42–0.77
Quintile V 0.38 0.27–0.50
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Table 1 (Continued)
Variable Base-case estimate Sensitivity range Source
CFR 0.0009 0.00063–0.00117 Based on incidence and [18]
Outpatient cost of seeking treatment $0.36 $0.25–$0.46
Outpatient treatment cost $3.12 $2.18–$4.05 [9]
Inpatient cost of seeking treatment $3.70 $2.59–$4.81
Inpatient treatment cost $74.26 $51.99–$96.54
Vaccination relative risk reduction 0.56 0.420–0.700 [44]
Vaccination baseline coverage 0.00%
UIP  cost per DPT3 child Based on cMYP and personal
communication with MoFWH
Baseline $22.50 $15.75–$29.25
Intervention one $27.00 $18.90–$35.10
Intervention two/three $23.50 $16.45–$30.55
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9.5. Analysis
.5.1. Simulated results from one year are analyzed in R
Analysis variables fall into four categories, which consider the
ntervention’s associated effect on disease burden, intervention
osts, cost-effectiveness, and ﬁnancial impact. The effect on dis-
ase burden includes both deaths and disability-adjusted life years
DALYs) averted (we discount at 3% and use uniform age-weights
hat value any extra year of life equally). Cost-effectiveness is mea-
ured by dollars per DALY averted incremental to the baseline
cenario. The ﬁnancial impact measures follow Verguet et al. [23]
nd include the out-of-pocket (OOP) expenditure averted from the
aseline scenario, which measures the savings of the population
hat result from the intervention, and the money-metric value of
nsurance, which measures the value of protection from expendi-
ure on disease treatment (including the costs of seeking care). The
oney-metric value of insurance here differs slightly from Ver-
uet et al.’s analysis. Our analysis period is one year as we study a
ross-section of the under-ﬁve population, while they study a birth
ohort, which is susceptible to disease over the ﬁrst ﬁve years of
ife. Given this, we include only one year of disposable income in
he calculation as opposed to ﬁve years. Additionally, we evalu-
te the value of insurance of an intervention with respect to the
aseline by subtracting one from the other. We  analyze health and
nancial burden alleviated across India by wealth quintile, state,
nd rural versus urban areas.
.6. Sensitivity analysis
To quantify the uncertainty of the model, we conduct a 100-
imulation Latin hypercube sampling (LHS) sensitivity analysis
ver a plausible range of the input parameters (Table 1). For each
isease, the parameters analyzed include the incidence, CFR, vac-
ine efﬁcacy, vaccine cost, and treatment cost. Ninety-ﬁve percent
ncertainty ranges for our mean estimated outcomes are calculated
n the basis of this sensitivity analysis and reported in parentheses.
. Results
In the baseline, immunization coverage is 77% for DPT3, 82%
or measles, and there is no coverage for rotavirus. From DLHS-
 data, we ﬁnd that baseline coverage increases by wealth for
PT3 and measles. The rural-to-urban immunization coverage ratio
s 1.09 for DPT3 and 1.05 for measles (Fig. 1, row 1). Baseline
PT3 coverage is lowest in Arunachal Pradesh and Uttar Pradesh
here 53% and 55% of under-ﬁves are vaccinated (Fig. 2, column
). Another nine states vaccinate less than 80% of their chil-
ren; all of them are relatively poor states, with the exception
f Gujarat (77% coverage). Eight states have DPT3 coverage above
0%. Measles vaccination coverage in six states is less than 80%;as with DPT3, coverage is lowest in Arunachal Pradesh (58%) and
Uttar Pradesh (60%). Twelve states are above 90% coverage for
measles, and Himachal Pradesh and Maharashtra are above 95%
coverage.
Our interventions decrease the coverage disparity between
wealth quintiles, rural and urban populations, and states. Interven-
tion two reduces the urban-to-rural vaccine coverage ratio for all
three vaccines to 1.03 (Fig. 1, row 1), though a total of 9 states
do not achieve 90% coverage for all vaccines, and measles cover-
age remains below 80% in Arunachal Pradesh and Uttar Pradesh
(Fig. 2). Intervention three equates urban and rural coverage (i.e.,
the urban-to-rural vaccine coverage ratio is approximately 1) and
makes coverage in each state at or above 90% for all three vac-
cines.
In the baseline scenario, India at large has 88.7 (95% uncertainty
range [UR], 85.1–92.4) rotavirus deaths per 100,000 under-ﬁves;
the rate is more than 60% higher in rural areas than in urban areas
(96.6 versus 59.8). Intervention one averts 34.7 (95% UR, 31.7–37.7)
deaths and 995 (95% UR, 910–1081) DALYs per 100,000 under-ﬁves
per year, roughly 44,500 deaths and 1.28 million DALYs throughout
the country. The number of deaths averted per 100,000 under-ﬁves
is 25.2 (95% UR, 19.9–30.5) in urban populations and 37.3 (95%
UR, 33.8–40.8) in rural populations (Fig. 1, row 2). Intervention
two averts another 22.1 deaths (95% UR, 18.6–25.7) per 100,000
under-ﬁves and 630 (95% UR, 522–737) DALYs per 100,000 for
all of the related diseases. Intervention three averts slightly more
deaths and DALYs than intervention two. Typically, the reduced
burden is highest for the poor and in rural areas (Fig. 1, row 2); this
trend is more pronounced in intervention three than in interven-
tion two.
Fig. 3 (total deaths averted from the baseline across all under-
ﬁves) and the ﬁrst row of Fig. 4 (DALYs averted across all under-ﬁves
in one year) map  the disease burden alleviated in all interventions.
In all states with sufﬁcient data, introducing the rotavirus vaccine
(intervention one) averts more than 15 rotavirus deaths and 450
DALYs per 100,000 under-ﬁves, though the standard deviations are
high. The intervention averts more than 45 deaths per 100,000 in
Karnataka, Uttarakhand, Andhra Pradesh, Himachal Pradesh, West
Bengal, Jammu and Kashmir and Bihar and more than 1500 DALYs
per 100,000 in Jammu  and Kashmir, Karnataka and Andhra Pradesh.
Intervention one costs almost $93 million per year for all of India.
The total intervention costs are mapped in Fig. 4, row 2. In interven-
tion one, the cost per 100,000 under-ﬁves ranges from $26,127 (95%
UR, $16,996–$35,257) in Arunachal Pradesh to $212,878 (95% UR,
$185,763–$239,994) in Delhi; the cost per 100,000 under-ﬁves in
Uttar Pradesh is low relative to other states (approximately 48,500),
but the state has the highest overall costs (approximately $14.1
million), taking into account the entire under-ﬁve population. The
urban-to-rural cost ratio is 1.17 (95% UR, 1.09–1.27) per 100,000
under ﬁves.
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Fig. 1. Analysis by rural and urban populations per 100,000 under-ﬁves in each.
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(esults are for 100 simulations. Conﬁdence intervals around the mean are from the
In interventions two (randomly increasing all three vaccines to
0% coverage) and three (increasing all three vaccines to at least
0% coverage in each region), states with low coverage rates in
ntervention one achieve the greatest additional reductions in bur-
en (Figs. 3 and 4, row 1). For example, Uttar Pradesh has the
econd lowest coverage in intervention one, and it averts an addi-
ional 427 (95% UR, 275–580) rotavirus-related DALYs per 100,000
nder-ﬁves per year in intervention two and 548 (95% UR, 372–724)
er 100,000 in intervention three. Approximately 665,000 DALYs
re averted for all ﬁve diseases in Uttar Pradesh in intervention
hree.The intervention costs incremental to the baseline in inter-
ention two for all ﬁve diseases are $137,926 (95% UR,
120,787–$155,065) per 100,000 under-ﬁves in Uttar Pradesh
$41 million for its entire population) and above $30,000 intivity analysis. OOP = out-of-pocket.
all other states. In intervention three, the cost incremental
to the baseline is above $100,000 in nine states, includ-
ing Uttar Pradesh, where the cost is $186,454 (95% UR,
$167,960–$204,948) per 100,000; the cost for all under-ﬁves in
Uttar Pradesh is approximately $53 million (Fig. 4, row 2). The
urban-to-rural cost ratio is 0.88 (95% UR, 0.54–1.41) in inter-
vention two and 0.75 (95% UR, 0.47–1.17) in intervention three
(Fig. 2).
Most of the OOP expenditure averted results from the reduced
rotavirus burden (Figs. 2 and 5, row 3): $232,354 (95% UR,
$224,029–$240,678) averted per 100,000 under-ﬁves in interven-
tion one, with an additional $49,489 (95% UR, $40,861–$58,118)
and $56,295 (95% UR, $47,599–$64,991) averted in interventions
two and three, respectively. The OOP averted for DPT (approx-
imately 1800) and measles (approximately 5500) is highest in
A156 I. Megiddo et al. / Vaccine 32S (2014) A151–A161
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iig. 2. Under-ﬁve immunization coverage.
esults are for 100 simulations. Rotavirus immunization is not available in the base
opulation are greyed out.
ntervention three (Fig. 4, row 3?). The urban-to-rural ratio of
OP expenditure averted decreases from intervention one through
ntervention three (Fig. 1, row 4; e.g., the rotavirus ratio decreases
rom 0.70 to 0.48).
The interventions are cost saving in all states that have sufﬁcient
ata. If we exclude OOP expenditure averted and only consider
he intervention costs, the incremental dollars per DALY averted
n intervention one is $70.89 (95% UR, 95% UR, $61.51–$80.28)
ith respect to the baseline. For interventions two and three,
he incremental dollars per DALY averted are $30.47 (95% UR,
$4.36–$65.28) and $36.97 (95% UR, $7.96–$65.97) with respect
o intervention one. Excluding OOP expenditure averted, the dol-
ars per DALY averted are below $110 in all states (with sufﬁcient
ample size) in all interventions.
The value of intervening is highest for rotavirus. In inter-
ention one, the money-metric value of insurance for rotavirus
anges from $521 (95% UR, $280–$761) per 100,000 under-ﬁves
n Delhi to $6756 (95% UR, $6318–$7196) in Bihar (Fig. 5). It is
ighest in intervention three in Bihar (approximately $7500 per
00,000 under-ﬁves) and Uttar Pradesh (approximately $5400 per
00,000). The values for DPT and measles are at or below $250 per
00,000 under-ﬁves in all states in all interventions. In all inter-
entions, the money-metric value of insurance decreases as wealth
ncreases.enario, and therefore the map  is greyed out. Additionally, states with a low sample
4. Discussion
In this paper we  present an ABM analysis for introducing a
rotavirus vaccine to the UIP and increasing UIP coverage to the 90%
goal set in the GIVS. We  analyze the effects across the wealth dis-
tribution, the rural and urban population distribution, and states.
The results do not present the exact beneﬁts and costs that would
be realized by implementing the intervention scenarios, but they
highlight the variation across population segments. The model is a
useful tool to understand which strategy and populations to target
when allocating scarce resources.
Immunization is one of the most cost-effective interventions for
improving health outcomes [24]. Even in a high-quality health sys-
tem, immunization policy addresses an important market failure:
individuals tend to under-vaccinate, and government intervention
is needed to ﬁx that failure. Though India has succeeded in elim-
inating polio, it has achieved less through routine immunization.
Targeted immunization campaigns may  be simpler to implement
than routine immunization. For example, the pulse polio campaign
involved a single-dose immunization. Routine vaccinations, how-
ever, may  require a more complex immunization delivery schedule
if several doses are required.
UIP coverage remains low in India, especially in certain sectors
of the population. Targeting expansion in these subpopulations in
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Fig. 3. Total under-ﬁve deaths averted from baseline.
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Lesults are for 100 simulations. DPT3 and measles vaccination coverage does not chan
overage is 90% or above in the baseline are greyed out in intervention three. Addit
ntervention three averts a greater burden than the random vac-
ination distribution in intervention two. This is partially because
overage is slightly higher than 90% in intervention three (a few
tates have higher-than-90% coverage in the baseline and maintain
hat coverage rate in intervention three). However, the simulation
esults also show that often the areas that suffer the highest dis-
ase burden and that have the greatest potential marginal gains to
accination are the areas that currently under-vaccinate the most.
lthough rural areas have lower rotavirus immunization cover-
ge than urban areas in intervention one, rural areas avert more
otavirus deaths in that scenario. Moreover, interventions tend to
ave a greater ﬁnancial beneﬁt for those segments of the popula-
ion. Poor and rural areas avert more deaths and OOP expenditure
han urban areas.
Demand and supply both contribute to low immunization rates.
ack of education contributes to low immunization demand. In aintervention one, and therefore the map  is greyed out. States in which immunization
, states with a low sample population or a high standard deviation are greyed out.
UNICEF survey of vaccination coverage in India, the most-cited rea-
sons for non-immunization included “did not feel the need,” “not
knowing about vaccines,” and “not knowing where to go for immu-
nization” [7]. Additionally, rural areas have poor access to health
care facilities. Where facilities are available, they often suffer from
stafﬁng issues and poor quality of service, which also decreases
health care demand [25].
The Indian immunization delivery system relies heavily on com-
munity health workers (CHWs) to mobilize and vaccinate the
rural population [26]. Strengthening CHW programs can increase
immunization coverage [26,27] and encourage age-appropriate
immunization [28]. Research suggests that providing incentives to
families can also improve vaccination rates [29]. However, effects
of these strategies have been little studied.
Although India is not currently reaching its target immunization
coverage with the UIP, it recognizes the potential of new vaccines.
A158 I. Megiddo et al. / Vaccine 32S (2014) A151–A161
Fig. 4. Health and ﬁnancial impact (totals by state).
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00%  demand for treatment. All interventions remain cost-effective if OOP expendi
t has introduced a new pentavalent vaccine in a few states [30] and
lans to roll it out across the country in 2014–15. Given the resource
onstraints, research into which vaccines alleviate the greatest
urden is important. A rotavirus vaccine is a compelling choice.
otavirus puts a heavy burden on the Indian population, especially
n under-two year olds, and does not signiﬁcantly decrease with
mprovements in hygiene and sanitation [31].
Our analysis of a rotavirus vaccine shows that its introduction
an signiﬁcantly reduce rotavirus burden. We  predict that introduc-
ng the vaccine at the DPT3 level will avert approximately 44,500
nder-ﬁve rotavirus deaths per year in India. Increasing rotavirus
mmunization coverage to 90% in our model averts approximately
nother 8500 and 9500 deaths in interventions two and three,
espectively; all three interventions are cost saving. Our results
or intervention one are similar to other cost-effectiveness mod-
ls [32,33]. Our DPT3 coverage, which is estimated for 2011, iseviation are greyed out. Values are in millions. OOP expenditure averted assumes
verted is excluded. DALYs = disability-adjusted life years; OOP = out-of-pocket.
higher than that of Esposito et al. [33]. The similar result despite
the disparity in vaccination coverage is because of different model
assumptions. Our death rate is lower and our vaccine efﬁcacy is
slightly higher. A recent report by the International Vaccine Access
Center (IVAC) at Johns Hopkins Bloomberg School of Public Health
[34] uses a baseline death rate much lower than ours (approx-
imately 54,000 versus 113,000) and estimates approximately
22,000 rotavirus deaths averted at 72% vaccination coverage. Their
cost averted differs signiﬁcantly from our OOP averted, though in
addition to different model parameters they include components
we do not (e.g. lost productivity). Verguet et al. [23] estimate (with
DLH-3 vaccination rates) the OOP expenditure averted for a 1 mil-
lion birth cohort and the money-metric value of insurance for 1
million households. Their cohort averts $1.8 million OOP expendi-
ture over the ﬁrst ﬁve years of life and the money-metric value of
insurance is $16,000 for 1 million households. We estimate that
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Fig. 5. Money-metric value of insurance per 100,000 under-ﬁves.
Results are for 100 simulations. DPT3 and measles vaccination coverage does not change in intervention one, and therefore the map  is greyed out. States in which immunization
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coverage is 90% or above in the baseline are greyed out in intervention three. Add
ut.  Money-metric value of insurance = the value of protection from the risk of exp
opulation is willing to pay to avoid that risk.
pproximately $2.3 million OOP is averted and a money-metric
alue of insurance of $23,500 summed over the wealth quintiles in
 cross-section 1 million population of under-ﬁves. We  sum over
ealth quintiles for comparability with their study, though wealth
uintiles do not include an equal number of under-ﬁve year olds.
ur results are similar, but the comparison is not exact due to the
iffering model populations and assumptions. The most signiﬁcant
ifference in model assumptions of the two analyses is the age
istribution of the under-ﬁve population.
The cost-effectiveness results here are more optimistic than
ther analyses [32,33] because of our assumption of 100% treat-
ent demand. If we do not consider OOP averted, we have a lower
ound estimate of cost-effectiveness, and the interventions remain
ery cost-effective by WHO’s cost-effectiveness criteria [35]: the
ost per DALY averted is less than India’s per capita GDP.lly, states with a low sample population or a high standard deviation are greyed
re on disease treatment (including the costs of seeking care). It is the amount the
The regional detail in the model is an additional reason for the
differences between our ﬁndings and past analyses. As discussed,
the marginal gains from immunization are often highest in areas
that currently vaccinate the least. Introducing rotavirus according
to DPT3 vaccination coverage (the same households) maintains that
trend.
A major challenge to realizing the potential beneﬁts described
here is the low investment in routine immunization [36]. In
2011–12 the MoHFW spent approximately $233 million on routine
immunization. Continuing the UIP at current coverage rates would
cost approximately $438 million in the intervention year (cMYP
and personal communication with MoHFW). The estimated cost for
the polio campaign during the intervention year is approximately
$108 million. Under the model assumptions, introducing a rotavirus
vaccine at DPT3 levels costs another approximately $93 million, or
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oughly a 17% increase on top of the total costs of the existing rou-
ine immunization and the polio campaign. Intervention three will
ost approximately $129 million more than would be spent in the
aseline ($53 million of which would be spent for Uttar Pradesh).
 signiﬁcant increase in immunization program funding is needed
oth to introduce the new vaccines and to increase immunization
overage in India.
The study is limited by the parameters we use. Though our anal-
sis focuses on the distribution across population subgroups, the
arameters do not capture all the covariates affecting these groups.
or example, we do not capture the state ﬁxed effects in many of our
ariables. We  use the population distributions (by age, wealth, and
ex) to extrapolate the values for speciﬁc subgroups. Additionally,
e assume that the per-child UIP costs are distributed uniformly
cross states. Despite not fully capturing all the factors affecting the
isease and expenditure distributions across the subpopulations,
e feel that this research is a step in the right direction. Addition-
lly, we do not model the infectious disease dynamics, which means
e do not consider any additional beneﬁts from herd immunity.
. Conclusion
Introducing a rotavirus vaccine to UIP and increasing UIP cov-
rage are cost-effective interventions that would greatly alleviate
he disease and ﬁnancial burden of vaccine-preventable diseases
n India. The results presented here are useful for policy analysis,
iven the paucity of data on the interventions’ effect size across dif-
erent subsets of the population: at the state level, in the rural and
rban populations, and across the wealth distribution. Additional
esearch is needed to introduce an infectious disease model into
he ABM used here and to take into account the state ﬁxed effects.
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